Focal Healthcare Announces FDA and Health Canada Clearance

Focal Healthcare (OBIO Pre-CAAP 2015) announced it has received both FDA 510(k) clearance and Health Canada approval for its Fusion Bx™ 2.0 prostate biopsy solution, which is now available for sale in the United States and Canada. 

Click here to read more

Previous
Previous

Conavi Medical Awarded Joule Innovation Grant

Next
Next

OBIO Opens Canadian Health Investment Showcase in New York City, Connecting Canada’s High Potential Health Science Companies with Premier US Investors